Empagliflozin in lupus mice. Two studies, opposite results: 🔹 Zhao, ARD 2023 🇨🇳: early use ↓proteinuria, ↓anti-dsDNA, improved podocyte autophagy. doi.org/10.1136/ard-... 🔹 Vilardell-Vilà, KI 2025 🇪🇸: no benefit when started during active nephritis. doi.org/10.1016/j.ki...

Dual BLyS/APRIL blockade with telitacicept improved systemic #lupus activity and reduced proteinuria in patients with moderate (and years after #nephritis onset) renal involvement. doi.org/10.1056/nejm...

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus | NEJM

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (S...

doi.org

We uncovered a powerful type I interferon signature in #ANCA #vasculitis, especially in MPA, tied to kidney prognosis, and close to lupus nephritis. 🚀 This opens exciting perspectives for IFN–targeted therapies in vasculitis. Full results presented at #KidneyWk @asnkidney.bsky.social in a few hours!

Groundbreaking work by @tharaux-lenoir-lab.bsky.social: blocking mineralocorticoid receptor signaling in parietal epithelial cells prevents crescentic GN. Shall we stop using methylpred pulses for AAV-GN induction, given their unwanted mineralocorticoid activity? doi.org/10.1016/j.kint.2025.07.037

Using kidney transcriptomics, we identified a robust 12-gene signature predicting renal survival in #ANCA #vasculitis, outperforming histopathology, and opening the way to precision medicine. Thank you for the highlight @asnpublications.bsky.social !

ASN Publications@asnpublications.bsky.social · last yr.

Large-scale kidney transcriptomics identified a 12-gene signature, including CLU and C3, predicting kidney failure in ANCA-associated vasculitis. Read more in #ASNJASN: kidney.pub/JASN0779 @benoitbrilland.bsky.social

Outstanding review that outlines evolving #ANCA #vasculitis treatments: from B-cell therapies (obinutuzumab, CAR-T) and T-cell therapies (ustekinumab) to new comers (T-cell engagers, alternative-pathway inhibitors, antifibrotics, ANCA–antigen blockers). A must read! www.nature.com/articles/s41...

Ex vivo #CRISPR-Cas9 knock out PR3 autoantigen in HSPCs prevents PR3-ANCA-driven neutrophil activation while preserving immune function. While aHSCT would still be required, this opens the door to sustained, drug-free remission in PR3 #ANCA #vasculitis! doi.org/10.1016/j.ki... @kidneyint.bsky.social

Targeting endothelial ferroptosis protects kidneys in #ANCA -associated #vasculitis, while systemic inhibition increases inflammation. This is why cell-specific therapies should be prioritised over blanket treatments! @kidneyint.bsky.social doi.org/10.1016/j.ki...

This new study shifts the focus from anti-MPO IgG to IgM in #ANCA -associated #vasculitis. IgM autoantibodies not only trigger potent complement activation but also dominate the autoreactive memory B cell pool—revealing a new pathogenic paradigm. Potential implications ⬇️

Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Our analysis from the french REIN registry ⬇️

@kireports.bsky.social · 2y ago

Kidney #Transplantation Improves Survival in Antineutrophil Cytoplasmic Antibody–Associated #ANCA #Vasculitides With End-Stage Kidney Disease #ESKD #VisualAbstract by @DrPSVali www.kireports.org/ar... @benoitbrilland.bsky.social

Last one: IV methylpred in very severe (eGFR<10 ml/min) #ANCA #vasculitis. Retrospective Chinese study, N=106, mostly MPO, high MMF use. IVMP (vs. no): higher dialysis independence (37% vs. 7%) & nearly significant lower mortality (19% vs. 37%, p = .056). bmcnephrol.biomedcentral.com/articles/10....

Maine-Anjou Research Group@maineanjoureg.bsky.social · 2y ago

IV methyl pred in severe (sCr > 500 or dialysis) #ANCA #vasculitis (observ.): no benefit for survival or renal recovery at M12. Higher risks of infections & diabetes with IVMP. Lower doses (1.5g total), more severe patients, MPO/PR3 more balanced than ⬇️. bmcnephrol.biomedcentral.com/articles/10....

IV methyl pred in severe (sCr > 500 or dialysis) #ANCA #vasculitis (observ.): no benefit for survival or renal recovery at M12. Higher risks of infections & diabetes with IVMP. Lower doses (1.5g total), more severe patients, MPO/PR3 more balanced than ⬇️. bmcnephrol.biomedcentral.com/articles/10....

Maine-Anjou Research Group@maineanjoureg.bsky.social · 2y ago

IV methylpred in "severe" #ANCA #vasculitis (observational study, target trial emulation): 1.0 g/day reduced 48-week mortality without increasing serious infections. 0.5 g/day showed limited effect. Limits: quite small number of subjects (201), mostly MPO. academic.oup.com/rheumatology...

IV methylpred in "severe" #ANCA #vasculitis (observational study, target trial emulation): 1.0 g/day reduced 48-week mortality without increasing serious infections. 0.5 g/day showed limited effect. Limits: quite small number of subjects (201), mostly MPO. academic.oup.com/rheumatology...

PEXIVAS post-hoc: no effect of reduced GC dose on kidney recovery in #ANCA #vasculitis. Faster kidney recovery with PLEX but not sustained beyond 3 months (better for subgroup GFR 15-30?). Real PLEX effect vs convection effect? @kronbichlerlab.bsky.social www.kidney-international.org/article/S008...

66% of #ANCA #vasculitis patients have coronary artery calcification (CAC score>0), indicating high cardiovascular risk, especially in MPO+. Only 25% are on statins. Urgent need for better screening and tailored cardiovascular prevention. rmdopen.bmj.com/content/11/1...

Infection is the top cause of death in #ANCA -associated #vasculitis, mostly during remission. Death certificates misreport causes, linking EHRs improves accuracy. We need to reduce infection risks through better immunosuppressive therapies www.sciencedirect.com/science/arti...

In #ANCA #vasculitis, 27% patients rated their health better or worse (≥ 20 PGA points) than their physicians did. This discordance highlights the need to address patients' perspectives to improve communication, shared decision-making, and care outcomes. pubmed.ncbi.nlm.nih.gov/39671122/

This study (aacrjournals.org/cancerimmuno...) shows that, in tumor-bearing mice, C5aR blockade boosts anti-PD1 efficacy by enhancing #antitumor immunity. Could these benefits translate to reducing long-term treatment-related adverse events in our #ANCA #vasculitis patients?

The C5a/C5aR1 axis promotes migration of tolerogenic dendritic cells to lymph nodes, impairing the anticancer immune response

Abstract. The precise mechanisms by which the complement system contributes to the establishment of an immunosuppressive tumor microenvironment (TME) and promotes tumor progression remain unclear. In ...

aacrjournals.org

First AI-driven model for grading #ANCA -associated #glomerulonephritis lesions achieves 93% accuracy. Grad-CAM heatmaps align with pathologists’ focus, enhancing prognosis reliability. Bonus: the heatmaps look like colorful PET scans of glomeruli! www.kireports.org/article/S246...

In #ANCA-associated renal #vasculitis, higher percentage of normal glomeruli in kidney biopsy predicts lower rates of ESKD. Maybe good for AI implementation, but… performance vs. standard classifications (Berden, AKRiS) and beyond 1 year unknown. www.kireports.org/article/S246...

Infections affect >50% of #ANCA -associated #vasculitis patients, with risk factors including diabetes, ESKD, kidney/lung involvement and treatment (methylprednisolone pulses, CYC, PLEX). Main site: respiratory system. Early risk management is crucial. doi.org/10.1016/j.au...

Brace yourself, next Vasculitis Workshop is coming! Key dates: ✅ Abstract submission: 28 March - 19 September 2025 ✅ Workshop dates: 21 - 25 February 2026 📍 Melbourne, Australia vasculitis-melbourne2026.com

IVW 2026 | 22nd International Vasculitis Workshop

Join the 22nd International Vasculitis Workshop, a leading event dedicated to advancing research, treatment, and understanding of vasculitis. Connect with global experts, researchers, and practitioner...

vasculitis-melbourne2026.com

Abatacept RCT vs placebo (on top of oral GC) in relapsing non severe granulomatosis #GPA #vasculitis (ABROGATE study): non superiority of abatacept. Relapse/worsening in 62% vs 68%. No difference in any secondary end-point (and SAEs). Dr. C. Langford #ACR24 acrabstracts.org/abstract/a-r...

Results of the TAPIR trial: glucocorticoid discontinuation in GPA #ANCA vasculitis. ▶️ higher number of relapse at 6 months for the discontinuation group ▶️ but driven by minor relapses and by subgroup not treated but Rituximab. Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)

Reduced GC dose in #ANCA vasculitis: @terrierben.bsky.social confirms PEXIVAS results in real life: no difference in death/ESKD. Larger composite criteria [see table] (that may be discussed) in favor of standard GC dose, especially for RTX patients and severe AKI ard.bmj.com/content/earl...

Welcome in @terrierben.bsky.social. The #vasculitis family is growing here on Bluesky!

Benoît Brilland@benoitbrilland.bsky.social · 2y ago

Moving from Twitter? Looking for #vasculits #glomerulonephritis lovers? Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!

20 years after their initial MPA model, Xiao, Falk & Jennette publish a groundbreaking paper (doi.org/10.1016/j.ki...). They introduce 3 new mouse models for #ANCA #vasculitis, using anti-MPO abs with different stimuli to mimic MPA, GPA, and EGPA phenotypes. 🧵1/5

Moving from Twitter? Looking for #vasculits #glomerulonephritis lovers? Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!